Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

June 01, 2021
ERADICATE (EA8183)
Prostate Cancer
Matthew Siegel, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

This phase III trial compares the effect of adding darolutamide to ADT versus ADT alone after surgery for the treatment of high-risk prostate cancer. ADT reduces testosterone levels in the blood. Testosterone is a hormone made mainly in the testes and is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. It also plays role in prostate cancer development. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. Giving darolutamide with ADT may work better in eliminating or reducing the size of the cancer and/or prevent it from returning compared to ADT alone in patients with prostate cancer.

Sponsor: ECOG-ACRIN

https://clinicaltrials.gov/ct2/show/NCT04484818

  • Less than 16 weeks since radical prostatectomy  
  • For patients with no previous Decipher score: Tumor tissue specimen from prostatectomy must be available and ready to be shipped
  • For patients who have previously had Decipher score performed by Decipher Biosciences, they must have score of >= 0.6
  • Must not have any previous treatment with androgen deprivation therapy, chemotherapy, or other physician prescribed systemic therapy for treatment of their prostate cancer
  • No evidence of pelvic lymph node involvement or cancer recurrence or metastasis 
3-5 years
Accepting Participants
Interventional
III
Sofia Mikac, BSN
630-646-6073
630-646-6074
630-646-6072